Analysts turn bearish on Roche’s taspoglutide prospects

After initially tapping taspoglutide as the latest in a string of likely blockbusters-to-be from Roche, analysts are turning sour on the drug's prospects after gaining a close look at the side effect data presented by researchers over the weekend. The once highly touted diabetes drug prospect was put through the ringer earlier in the month when Roche said that it needed to amend trials to watch for side effects like vomiting and nausea, delaying any app for up to 18 months. But a look at...